Ironwood Pharmaceuticals, Inc.

NasdaqGS:IRWD 주식 보고서

시가총액: US$887.0m

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Ironwood Pharmaceuticals 관리

관리 기준 확인 3/4

Ironwood Pharmaceuticals' CEO는 Tom McCourt, Mar2021 에 임명되었습니다 의 임기는 3.25 년입니다. 총 연간 보상은 $ 7.58M, 11% 로 구성됩니다. 11% 급여 및 89% 보너스(회사 주식 및 옵션 포함). 는 $ 2.92M 가치에 해당하는 회사 주식의 0.32% 직접 소유합니다. 2.92M. 경영진과 이사회의 평균 재임 기간은 각각 2.6 년과 5.2 년입니다.

주요 정보

Tom McCourt

최고 경영자

US$7.6m

총 보상

CEO 급여 비율11.0%
CEO 임기3.3yrs
CEO 소유권0.3%
경영진 평균 재임 기간2.6yrs
이사회 평균 재임 기간5.2yrs

최근 관리 업데이트

Recent updates

Ironwood Pharmaceuticals: Q3 Of 2024 Data Readout For PBC

Jun 20

Ironwood Pharmaceuticals, Inc.'s (NASDAQ:IRWD) Price Is Right But Growth Is Lacking After Shares Rocket 28%

Feb 16
Ironwood Pharmaceuticals, Inc.'s (NASDAQ:IRWD) Price Is Right But Growth Is Lacking After Shares Rocket 28%

Ironwood Pharmaceuticals: Capitalizing On GI Healthcare's Growing Potential

Jan 31

Revenues Working Against Ironwood Pharmaceuticals, Inc.'s (NASDAQ:IRWD) Share Price

Dec 19
Revenues Working Against Ironwood Pharmaceuticals, Inc.'s (NASDAQ:IRWD) Share Price

Ironwood Pharmaceuticals (NASDAQ:IRWD) Seems To Use Debt Rather Sparingly

Jul 25
Ironwood Pharmaceuticals (NASDAQ:IRWD) Seems To Use Debt Rather Sparingly

An Intrinsic Calculation For Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Suggests It's 39% Undervalued

Apr 18
An Intrinsic Calculation For Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Suggests It's 39% Undervalued

Ironwood Pharmaceuticals (NASDAQ:IRWD) Could Easily Take On More Debt

Mar 28
Ironwood Pharmaceuticals (NASDAQ:IRWD) Could Easily Take On More Debt

Ironwood Pharmaceuticals: Rinse, Wash And Repeat

Oct 05

These 4 Measures Indicate That Ironwood Pharmaceuticals (NASDAQ:IRWD) Is Using Debt Safely

Sep 28
These 4 Measures Indicate That Ironwood Pharmaceuticals (NASDAQ:IRWD) Is Using Debt Safely

Ironwood Pharma falls 7% as Linzess Q2 sales of drug from AbbVie weigh

Jul 29

CEO 보상 분석

Tom McCourt 의 보수는 Ironwood Pharmaceuticals 의 수익과 비교하여 어떻게 변경되었나요?
날짜총 보상급여회사 수익
Mar 31 2024n/an/a

-US$1b

Dec 31 2023US$8mUS$834k

-US$1b

Sep 30 2023n/an/a

-US$952m

Jun 30 2023n/an/a

-US$917m

Mar 31 2023n/an/a

US$182m

Dec 31 2022US$8mUS$805k

US$175m

Sep 30 2022n/an/a

US$168m

Jun 30 2022n/an/a

US$173m

Mar 31 2022n/an/a

US$527m

Dec 31 2021US$9mUS$732k

US$528m

Sep 30 2021n/an/a

US$530m

Jun 30 2021n/an/a

US$509m

Mar 31 2021n/an/a

US$143m

Dec 31 2020US$3mUS$576k

US$106m

Sep 30 2020n/an/a

US$111m

Jun 30 2020n/an/a

US$97m

Mar 31 2020n/an/a

US$84m

Dec 31 2019US$5mUS$511k

US$59m

Sep 30 2019n/an/a

US$19m

Jun 30 2019n/an/a

-US$153m

Mar 31 2019n/an/a

-US$173m

Dec 31 2018US$2mUS$465k

-US$194m

Sep 30 2018n/an/a

-US$190m

Jun 30 2018n/an/a

-US$71m

Mar 31 2018n/an/a

-US$108m

Dec 31 2017US$2mUS$450k

-US$55m

보상 대 시장: Tom 의 총 보상 ($USD 7.58M )은 US 시장( $USD 3.43M ).

보상과 수익: Tom 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Tom McCourt (67 yo)

3.3yrs

테뉴어

US$7,583,270

보상

Mr. Thomas A. McCourt, also known as Tom, serves as Director at Pliant Therapeutics, Inc. since March 08, 2023. He serves as Chief Executive Officer and Director of Ironwood Pharmaceuticals, Inc. since Jun...

리더십 팀

이름위치테뉴어보상소유권
Thomas McCourt
CEO & Director3.3yrsUS$7.58m0.32%
$ 2.9m
Sravan Emany
Senior VP2.5yrsUS$2.76m0.099%
$ 876.5k
John Minardo
Senior VP2.8yrsUS$2.44m0.074%
$ 653.6k
Michael Shetzline
Chief Medical Officer5.4yrsUS$2.60m0.16%
$ 1.4m
Andrew Davis
Senior VP & Chief Business Officer2.4yrsUS$2.67m0.11%
$ 932.1k
Ronald Silver
Corporate Controller & Principal Accounting Officer5.2yrs데이터 없음0.029%
$ 253.2k
Greg Martini
Vice President of Strategic Finance & Investor Relationsno data데이터 없음데이터 없음
Beth Calitri
Head of Corporate Communications & Media Relations2.4yrs데이터 없음데이터 없음
Mike Nanfito
Vice President of Sales & Sales Excellence2.8yrs데이터 없음데이터 없음
Susanna Huh
VP & Head of Clinical Development1.8yrs데이터 없음데이터 없음
Jana Noeldeke
Basel Site Head & Apraglutide Lifecycle Leader1.4yrs데이터 없음데이터 없음
Matt Roache
Director of Investor Relationsno data데이터 없음데이터 없음

2.6yrs

평균 재임 기간

47yo

평균 연령

경험이 풍부한 관리: IRWD 의 관리팀은 경험 ( 2.6 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름위치테뉴어보상소유권
Thomas McCourt
CEO & Director3yrsUS$7.58m0.32%
$ 2.9m
Jay Shepard
Independent Director3.5yrsUS$300.71k0.064%
$ 570.5k
Perry Halushka
Member of Pharmaceuticals Advisory Committeeno data데이터 없음데이터 없음
Alexander Denner
Independent Director3.6yrsUS$300.69k0.078%
$ 694.8k
Mark Currie
Independent Director5.2yrsUS$300.71k0.34%
$ 3.0m
Andrew Dreyfus
Independent Director8.2yrsUS$310.71k0.10%
$ 914.7k
Michael Mendelsohn
Member of Pharmaceutical Advisory Committee7.3yrs데이터 없음데이터 없음
Catherine Moukheibir
Independent Director5.2yrsUS$310.69k0.031%
$ 271.4k
Julie McHugh
Independent Chairman of the Board10.3yrsUS$335.71k0.088%
$ 778.6k
Marla Kessler
Independent Director5.2yrsUS$300.71k0.061%
$ 538.8k
Jon Duane
Independent Director5.2yrsUS$305.71k0.076%
$ 675.3k

5.2yrs

평균 재임 기간

65yo

평균 연령

경험이 풍부한 이사회: IRWD 의 이사회는 경험(평균 재직 기간 5.2 년)으로 간주됩니다.